Cytomedix gets $13M in RDO

Cytomedix says it has landed approximately $13 million in current and future funding via a registered direct offering and commitments under two separate equity purchase agreements. The company is developing regenerative therapies for wound care, inflammation and angiogenesis. Cytomedix release

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.